• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patentanwaltskanzlei

Patentanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees‘ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Walter Benjamin Feldheim
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

Medical devices in trademark law different to patent law

25. November 2019

While patent law explicitly distinguishes between products for medical and non-medical purposes, the medical purpose is not decisive for a medical devices in trademark law: likelihood of confusion between Floramed and Medilflor.

Medical devices in trademark lawThe Court of Justice of the European Union (CJEU) ruled on Wednesday in Floramed vs. Mediflor (EU:T:2019:794) that goods are identical and highly similar, although non-medical products have been compared with medical products. Patent law, on the other hand, makes an explicit and consequential distinction between these two groups of products.

The facts

The Union figurative mark Floramed was registered by Manfred Scheffler (Germany) as a Union figurative mark and was taken over by his legal successor and plaintiff Stefan Werner (Germany). The intervener, Merck KGaA (Germany), filed an opposition against the registration of the trade mark and claimed that there was a likelihood of confusion with its own earlier Union wordmark Mediflor.

The Opposition Division and also the Board of Appeal of the EUIPO (17 September 2018 (‘the contested decision’)) had identified a likelihood of confusion between the marks at issue within the meaning of Article 8(1)(b) of Regulation 2017/1001. There is a likelihood of confusion for all the goods in question because the marks at issue consist of two almost identical elements, namely “med” or “medi” on the one hand and “flora” or “flor” on the other.

Relevant Public with an increased degree of attention

It was undisputed in this case that the specialist public should be classified with an increased degree of attention. It follows, as a general rule, that there is a likelihood of confusion between the marks and the goods covered even if the similarity is less pronounced. The global assessment of the likelihood of confusion implies some interdependence between the relevant factors, as the CJEU pointed out.

Medical purpose not decisive

The applicant argued that food supplements for non-medical purposes should not be equated with products for medical purposes. The Board of Appeal erred in finding that dietary foods for non-medical purposes meet the particular nutritional requirements for the prevention of a disease.

The CJEU rejected this. The goods covered by the marks at issue are identical because they overlap. In addition, the “pharmaceutical preparations” and the “pharmaceutical products” are also identical. According to settled case-law, goods may be regarded as identical if the goods covered by the earlier mark are contained in a more general category to which the trade mark application relates, the Court explained. That is clearly the case here for all the above-mentioned goods covered by the earlier mark in relation to the more general categories of goods for medical or pharmaceutical use.

Medical devices in trademark law

The European Court also identified other relevant factors. Non-medical products, like medical products in general, are manufactured by the same pharmaceutical companies and distributed through the same channels, in particular pharmacies, and are often aimed at the same consumers, the CJEU stated. And both products should maintain or improve their health.

The CJEU ruled that the plaintiff could not call these common features into question on the grounds that products for medical purposes differed from products for non-medical purposes because only the former served to treat or cure a disease. Such reasoning is based on an overly narrow understanding of medical purposes, which, according to the description of “medical devices” in Class 5, includes “detection, prevention, monitoring, treatment and alleviation of disease, injury or disability”.

In this context, you would also like to read: Exhaustion of trademark rights – for medical devices?

Medical devices in patent law

Patent law makes an explicit and detailed distinction between products for medical purposes and medical devices. A supplementary protection certificate (SPC) can only protect a product that is used as a medicinal product, but not a medical device (please read: SPC not permitted for medical devices). This applies even if a component of the medical device complies with pharmaceutical standards, the CJEU ruled in November 2018.

In its recent ruling on Floramed, the CJEU confirmed a similarity between the marks in dispute. The components “med” and “medi” are descriptive for all goods in question and therefore played only a minor role in the comparison of the signs, the CJEU ruled. Also “flora” is purely descriptive, both for the plant world and for the intestinal flora. Therefore, it cannot be argued that “flora” is an imaginary term or has distinctive character.

Reverse order of the word elements without influence

In addition, the two marks in dispute, Floramed vs. Medilflor, have a reverse order of almost identical verbal elements. In the similar case Pink Lady vs. Wild Pink, the CJEU found a likelihood of confusion in 2018. The mere reversal of these elements in the conflicting signs has only a minor influence on the comparison between them, the CJEU also ruled in the present case Floramed. The relevant public cannot remain unaware that these main word elements, of which the signs consist in reverse order, are almost identical, all the more so as the degree of attention of the specialist public is increased.

The CJEU therefore confirmed the decision of the Board of Appeal and the likelihood of confusion between the two marks and dismissed the action.

Are you looking for advice on trademark law, patent protection or SPC?

Then take advantage of our offer for a recall appointment!

Our patent and law firm has many years of expertise in the protection of patents, particularly in the field of pharmaceuticals and medical devices, both nationally and internationally.

 

Sources: 

Judgement European Court  Floramed vs. Mediflor EU:T:2019:794

Image:

ulleo / www.pixabay.com / CCO License

  • share  
  • share 
  • share 
  • share 
  • share 

Category iconHealthcare & Lifesciences,  Trademark Law Tag iconalmost identical word elements,  class 5,  Floramed vs. Mediflor,  goods for medical or pharmaceutical use,  likelihood of confusion,  medical device Floramed,  medical device in trademark law,  medical devices,  medical purpose,  patent law,  pharmaceutical product,  reverse order,  Trademark law,  Union figurative mark,  wordmark

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More articles about: Healthcare & Lifesciences

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law

Recent Posts

  • What is the public allowed to know? 3. June 2024
  • BPatG: Patent claim of cancer drug on active substance as salt 7. March 2022
  • Grant for European IP Protection: SME Fund 2022 4. March 2022
  • CODE-X vs. Cody’s: Likelihood of confusion in drinks? 25. February 2022

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

3. June 2024
What is the public allowed to know?

What is the public allowed to know?

7. March 2022
BPatG: Patent claim of cancer drug on active substance as salt

BPatG: Patent claim of cancer drug on active substance as salt

4. March 2022
Grant for European IP Protection: SME Fund 2022

Grant for European IP Protection: SME Fund 2022

25. February 2022
CODE-X vs. Cody’s: Likelihood of confusion in drinks?

CODE-X vs. Cody’s: Likelihood of confusion in drinks?

24. February 2022
EOS lip balm no 3D trademark – appeal before ECJ not admissible

EOS lip balm no 3D trademark – appeal before ECJ not admissible

21. February 2022
CFI: Pumpkin seed oil + PGI symbol

CFI: Pumpkin seed oil + PGI symbol

Contact us or request a call back

+49 (0) 69 / 606 278 – 0
[email protected]
Request a call back

Footer

Contact

Hanauer Landstrasse 287
D – 60314 Frankfurt am Main
Deutschland
+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Office Hours
Moday – Friday:   08:00-18:00

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • LinkedIn
  • xing
  • Email

Newsletter Signup

Newsletter INT

© Meyer-Dulheuer MD Legal Patentanwälte PartG

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

Rückruf INT

Please note: If we deal specifically with your individual case, this is what is known as an initial consultation. In accordance with Section 34 of the Rechtsanwaltsvergütungsgesetz, this incurs one-off costs of 190 euros plus MwSt. We will be happy to assist you in a personal consultation after our telephone call.

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]

Rückruf

Um dieses Angebot nutzen zu können, müssen Sie der Speicherung Ihrer personenbezogenen Daten zustimmen. Wir behandeln diese streng vertraulich und verwenden sie nur zur Kontaktaufnahme mit Ihnen. Mehr dazu lesen Sie in unserer Datenschutzerklärung.

Bitte beachten Sie: Wenn wir uns konkret mit Ihrem Einzelfall befassen, ist dies eine sogenannte Erstberatung. Für eine solche entstehen gemäß § 34 Rechtsanwaltsvergütungsgesetz einmalige Kosten in Höhe von 190 Euro plus MwSt. Gerne helfen wir Ihnen im Anschluss an unser Telefonat in einem persönlichen Beratungsgespräch weiter.